Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Amgen's Humira Biosimilar Gains Nod From Panel Perplexed By Regulatory Pathway

Executive Summary

Time and again, FDA officials had to explain the importance of the analytical characterization data in the biosimilar development paradigm.


Related Content

Amgen/Allergan Target Lucrative Avastin Market With Another Biosimilar Filing
Celltrion's Biosimilar Strategy Includes Simultaneous EMA/FDA Reviews
Amgen's Amjevita Approved As First Biosimilar To AbbVie's Humira
Biosimilar User Fee Agreement Offers FDA Funding Boost, Fee Structure Overhaul
Medicare Value-Based Model May Provide Test For Biosimilars – At Some Point
Lobbying FDA: AbbVie Questions Humira Biosimilars In Private Meeting
Sandoz Steers Enbrel Biosimilar Away From Equivalence Quandary With Reanalysis
Biosimilars: Does FDA Caution Make Advisory Committee A Rubber Stamp?
Biosimilar Doubleheader: Amgen's Humira Competitor Pitching First To FDA
Extrapolated Biosimilar Indications Won't Get More Post-Marketing Requirements


Related Companies